Amedex Therapeutics, Inc. is Issued NuBiotics Patent.

WILSONVILLE, Ore. -- Amedex Therapeutics, Inc.[TM] (ATI), formerly Nu Pharmas, Inc., a biopharmaceutical company developing its NuBiotics portfolio of unique anti-infective products targeted to bacterial infections, encompassing antibiotic resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and also certain viral indications including avian influenza, Epstein Barr Virus (EBV) and hepatitis B and C, announced today that it has been issued a fourth NuBiotics patent by the U.S. patent office.

Steve Parkinson, ATI's President and Chief Executive Officer, commented "This fourth patent, in combination with the previous three in this series, already granted, gives ATI a very strong position in its unique, first-in-class anti-microbial NuBiotics products." Parkinson continued, "The biopharmaceutical industry has brought surprisingly few new antibiotics to market in recent years, but interest in this area has returned significantly because infectious disease has re-emerged as a major clinical challenge."

Dr. Roderic Dale, founder and Chief Scientific Officer said. "NuBiotics are a unique class of compounds based on modified nucleotide chemistry developed within the company. They have shown to be effective at killing a large variety of pathogenic bacteria, including MRSA and other antibiotic resistant bacteria in MIC assays, animal models and in human patients. In addition, our proprietary anti-viral products target the viral genetics, while being completely harmless to the human patients."

Mr. Parkinson said "ATI has a substantial pipeline of anti-bacterial and anti-viral products at various stages of development and we believe the company is poised to become a significant player in the anti-infectives arena in the next few years."

About Amedex Therapeutics, Inc.

ATI is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 46 patent applications covering its proprietary NuBiotics family of anti-microbial and anti-fungal products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant stains including MRSA and others, and patents covering certain proprietary products targeted at problematic viral infections including, Epstein Barr Virus (EBV), avian influenza, hepatitis B and C and other clinical indications. The Company anticipates initiating human clinical trials for topical use of its Nu-3 NuBiotics compound in the near future for indications including; diabetic ulcers, athletes foot, cold sores, topical infections and acne. Future studies will involve the use of Nu-3 or other members of the NuBiotics family to treat MRSA infections and antibiotic-resistant bacterial pulmonary and systemic infections. ATI also expects to initiate clinical studies to combat EBV associated with nasopharyngeal carcinoma, and cachexia (muscle wasting) associated with AIDS patients in Beijing, China, later this year.

ATI wholly owns two operating subsidiary companies as follows;

* Oligos Etc, Inc. (OEI), a seventeen year old established profitable contract manufacturer of oligonucleotide compounds, founded by Dr. Dale in 1989.

* The pharmaceutical operation includes a wholly-owned subsidiary in Beijing China focused on discovery, preclinical and clinical studies and formal clinical trials to generate supporting human efficacy data for the Company's lead pharmaceutical candidates.